SAFETY, TOLERABILITY, AND ANTIVIRAL ACTIVITY OF THE siRNA VIR-2218 IN COMBINATION WITH THE INVESTIGATIONAL NEUTRALIZING MONOCLONAL ANTIBODY VIR-3434 FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION: PRELIMINARY RESULTS FROM THE PHASE 2 MARCH TRIAL